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Abstract 14 
In order to establish the environmental impact of an active pharmaceutical ingredient (API), 15 
good information on the level of exposure in surface waters is needed. Exposure 16 
concentrations are typically estimated using information on the usage of an API as well as 17 
removal rates in the patient, the wastewater system and in surface waters. These input data 18 
are often highly variable and difficult to obtain, so model estimates often do not agree with 19 
measurements made in the field. In this paper we present an approach which uses inverse 20 
modelling to estimate overall removal rates of pharmaceuticals at the catchment scale using a 21 
hydrological model as well as prescription and monitoring data for a few representative sites 22 
for a country or region. These overall removal rates are then used to model exposure across 23 
the broader landscape. Evaluation of this approach for APIs in surface waters across England 24 
and Wales showed good agreement between modelled exposure distributions and available 25 
monitoring data. Use of the approach, alongside estimates of predicted no-effect 26 
concentrations for the 12 study compounds, to assess risk of the APIs across the UK 27 
landscape, indicated that, for most of the compounds, risks to aquatic life were low. 28 
However, ibuprofen was predicted to pose an unacceptable risk in 49.5% of the river reaches 29 
studied. For diclofenac, predicted exposure concentrations were also compared to the 30 
Environmental Quality Standard previously proposed by the European Commission and 4.5% 31 
of river reaches were predicted to exceed this concentration. While the current study focused 32 
on pharmaceuticals, the approach could also be valuable in assessing the risks of other ‘down 33 
the drain’ chemicals and could help inform our understanding of the important dissipation 34 
processes for pharmaceuticals in the pathway from the patient to ecological receptors. 35 
 36 
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Introduction 40 
 41 
During the life cycle of a pharmaceutical product, Active Pharmaceutical Ingredients (APIs) 42 
may be released to the natural environment
 
(Daughton and Ternes, 1999; Boxall, 2004) and a 43 
wide range of APIs have been detected in surface waters (Hirsch et al., 1999; Kolpin et al., 44 
2002; Monteiro and Boxall, 2010). Even though the reported concentrations are generally low 45 
(i.e. sub-µg/l), questions have been raised over the potential impacts of APIs in the 46 
environment on flora and fauna and human health. Environmental risk assessments are also 47 
now required in many regions as part of the marketing authorisation process of a new API
 
48 
(Breton and Boxall, 2003). In order to establish the risks of APIs, it is essential to have a 49 
good understanding of the levels of exposure that occur in natural systems. 50 
A range of exposure modelling approaches is currently being applied in the assessment of the 51 
environmental risks of APIs. These include simple deterministic algorithms through to more 52 
complex models such as the GREAT-ER, PhATE and LF2000-WQX models
 
(EMA, 2006; 53 
Schowanek and Webb, 2002; Schwab et al., 2005; Williams et al., 2009) which use data on 54 
flow in rivers to estimate how APIs will be distributed within river catchments. In order to 55 
accurately estimate concentrations in the environment, these models traditionally require 56 
comprehensive information on the usage of an API within the system of interest, the extent of 57 
metabolism of the API within treated humans and the degree of removal in wastewater 58 
treatment processes and in receiving waters. 59 
Many countries collate detailed information on the quantities of APIs used. For example, in 60 
the UK, the National Health Service collect monthly information on the number of 61 
prescriptions made for different products in different regions. From this freely available 62 
information, it is possible to determine the amounts of different APIs prescribed in an area 63 
over time. Similar systems are in place in Denmark, Germany and Australia. However, the 64 
estimation of API usage, based on prescription volumes, may over-estimate what is actually 65 
released to the environment. Over half of patients store unused medicines in their home as a 66 
consequence of dosage changes, discontinuation of the medication due to, for example, the 67 
occurrence of adverse side effects, or because the medications have reached their expiry date. 68 
It is estimated that anywhere between 3 and 65% of prescribed pharmaceuticals are not used 69 
and many of these will ultimately be returned to the pharmacist or disposed of to landfill
 
70 
(Seehusen and Edwards, 2006; Musson and Townsend, 2009). 71 
While numerous publications are available on the metabolism of APIs, the results of these 72 
studies can be highly variable. For example, for cyclophosphamide (one of the APIs 73 
investigated in the current study), amounts excreted are reported to range from 2 to 25% of 74 
the applied dose
 
(Bagley et al., 1973). The observed differences are probably explained by 75 
genomically distinct metabolising capacities as well as differences in race, sex, age and 76 
health status of the studied subjects, all of which are known to affect the route and rate of 77 
metabolism
 
(Dorne, 2010). The method of administration, previous exposure of a patient to 78 
the pharmaceutical and simultaneous exposure to other APIs and xenobiotics can also affect 79 
the degree of metabolism. 80 
For many APIs, no data exist on removal in wastewater treatment. In instances where data are 81 
available, variations can also be seen in the reported removal efficiencies
 
(Sipma et al., 82 
2010). These variations can be explained by differences in technologies used at different 83 
treatment works and differences in operating parameters. Some metabolites may also be re-84 
converted back to the parent compound in wastewater treatment
 
(Heberer et al., 2002). In 85 
large catchments it is likely that numerous treatment technologies will be in use and that 86 
these will vary in size and performance, so a variety of removal rates may need to be 87 
employed in the modelling. The fate of substances in the sewer system is also unknown. 88 
Finally, available data on dissipation of APIs in receiving waters is mostly generated under 89 
controlled laboratory conditions and dissipation in natural aquatic systems is often much 90 
slower than in the laboratory
 
(Fono et al., 2006). When all of these different factors are 91 
considered, it is perhaps not surprising that the selection of the input parameters for exposure 92 
modelling for APIs can be challenging and that, while some exposure modelling of this type 93 
has been successful for some contaminants (Ort et al., 2009), predictions do not always agree 94 
with observed measurements of APIs in the field
 
(Metcalfe et al., 2008).  95 
One approach to overcome the problem of the parameter selection process is to use 96 
monitoring data alongside inverse modelling to derive model input parameters. In this 97 
approach, data on measured concentrations of APIs within a study system are used in the 98 
models to back calculate one or more model input parameter. The derived parameters can 99 
then be employed to model exposure in other scenarios. The advantage of this approach in 100 
API exposure modelling is that it accounts for variability in factors such as metabolism of 101 
APIs within the population in the catchment; dissipation in the sewer network; effects of 102 
different types of treatment technologies that are employed; and the different dissipation 103 
processes that occur in surface waters. Inverse modelling, based on data on environmental 104 
occurrence, has already successfully been used to estimate usage of illicit drugs for different 105 
regions around the world
 
(Zuccato et al., 2011) and emissions and half-lives of selected APIs 106 
into/in European surface waters (Pistocchi et al., 2012).  107 
In this paper we present and evaluate a combined monitoring and modelling approach that 108 
uses prescription and monitoring data to estimate removal of pharmaceuticals between the 109 
point of use and emission into surface waters. We then show how the removal estimates can 110 
be used to estimate concentration distributions for API in water bodies at the landscape scale. 111 
We illustrate the utility of the approach by assessing the risks of 12 commonly used APIs 112 
across surface waters in England and Wales.  113 
1. Methods 114 
1.1.Monitoring data 115 
The measured data on concentrations of APIs in surface waters was taken from a recent study 116 
into the occurrence of APIs in surface and drinking waters in England and Wales
 
(Boxall et 117 
al., 2012a). The twelve study APIs (Table 1) covered a range of chemical classes and varied 118 
in terms of their physico-chemical properties. The study was carried out at four catchments, 119 
which varied in terms of the population served and in the type of wastewater treatment 120 
technologies employed (Table 2). Triplicate samples of surface water (2.5 L) were taken from 121 
a single point in each catchment every 4 weeks for a period of 12 months. Following 122 
collection, these were immediately transported back to the laboratory where they were 123 
extracted onto HLB solid phase extraction cartridges before being analysed by LC-MS/MS 124 
using a Waters Acquity Ultra-Performance Liquid Chromatography (UPLC) system (Waters, 125 
Milford MA, US) fitted with a UPLC HSS T3 C18 column. Gradient elution was used with 126 
mobile phases consisting of 5 mM ammonium acetate in water and methanol. Concentrations 127 
were determined by comparison of peak areas with those of known matrix-matched 128 
standards. For a number of analytes (atenolol, carbamazepine, fluoxetine and ibuprofen), 129 
internal standards, comprising the deuterated form of the compound, were used to correct for 130 
losses during the extraction process and/or suppression or enhancement of the MS signal. In 131 
the event that internal standards were not available, sample over-spiking at a range of 132 
concentrations was used to assess recovery of a compound. Seven of the 12 study compounds 133 
were detected in surface waters at sub-µg/l concentrations. Mean concentrations and 134 
concentration ranges are shown in Table 1.   135 
 136 
1.2.Model Description 137 
The modelling was carried out using the LF2000-WQX model
 
(Williams et al., 2009), which 138 
is a spatially-based modelling framework that has been widely applied to a number of 139 
chemicals discharged down-the-drain
 
(Williams et al., 2009; Rowney et al., 2009; Price et al., 140 
2010a and b; Janna et al., 2011) and so only the parts salient to this analysis will be described 141 
here. LF2000-WQX is the water quality extension model to the Low Flows 2000 (LF2000) 142 
software system
 
(Young et al., 2003; Environment Agency, 2004), which is a geographical 143 
information system (GIS) based decision support tool designed to estimate river flows at 144 
ungauged sites. It combines hydrological models estimating the magnitude and variability of 145 
flows across a catchment with a water quality model. The water quality model is driven by 146 
discharges from sewage treatment plants (STPs), the locations of which are preset in the 147 
model along with data describing the population served, treatment type and dry weather flow 148 
of each works. The outputs of the model are mean and 90th and 95th percentile 149 
concentrations for each river reach within the catchment being modelled. 150 
Calculation of concentrations in river reaches is based on a simple mass balance mixing 151 
equation which is applied in an iterative Monte Carlo simulation using the method of 152 
combining distributions proposed by Warn and Brew
 
(Warn and Brew, 1980). Point-source 153 
effluent emissions are combined with reach-specific flow statistics to calculate in-river 154 
concentrations after mixing at the point of discharge, allowing for upstream concentrations of 155 
the pharmaceutical. Flow in the river and flow volume from the sewage works are described 156 
as distributions. The other parameters are held constant. The river flow is characterised as 157 
log-normal and the sewage works flows as normal. Changes in concentration with ‘flow time’ 158 
due to dilution, from e.g. inputs from tributaries, and degradation also are calculated.   159 
The emissions of an API for a given STP are typically derived from prescription data and 160 
STP characteristics. The STP inflow concentration (Ci) is estimated from the projected/actual 161 
per capita mass of chemical used/excreted (M, µg/cap/day), and the STP dry weather flow 162 
(DWF, L/day), using Equation 1:  163 
 164 
DWF
PM
Ci

      Equation 1 165 
Where P is the population served by the works and was obtained from the water utilities 166 
operating each works for all works across England and Wales. A normal distribution is 167 
assumed for DWF. The other parameters are fixed for each sewage treatment works. 168 
The model allows removal in treatment efficiency to be considered using a global removal 169 
rate (r) including sewer removal, primary treatment and secondary treatment. The value of r 170 
can be specific to each STP modelled and can be varied according to the type of plant and 171 
levels of treatment applied. The final concentration in the effluent (Ceff), is thus 172 
 173 
)1( rCC ieff       Equation 2 174 
 175 
Equations 1 and 2 describe the STP process. They are calculated in turn for each of the Monte 176 
Carlo iterations, so that the point source emission is expressed as a distribution.  177 
Within LF2000-WQX, the whole catchment is structured as a network of interconnected 178 
model reaches. Reaches are defined as river stretches between model features, which are 179 
usually defined by significant tributaries, confluence of model reaches and STPs. Within the 180 
river, the model can simulate either conservative (no in-stream removal) or degradable (in-181 
stream removal) substances. Modelling a degradable determinand, the concentration 182 
downstream (CDS), after in-stream removal is defined with a first order exponential decay:  183 
 184 
tk
EPDS eCC
      Equation 3 185 
 186 
Where CEP is the concentration in the river at the point of entry of an STP discharge, k (day
-1
) 187 
is the decay rate, and t (day) is the time of travel along a reach defined as the reach length 188 
divided by the velocity of the river. 189 
 190 
1.3. Estimation of removal of APIs using inverse modelling and comparison with removal 191 
estimates using standard modelling approach 192 
Inverse modelling was used to estimate the mean, maximum and minimum removal of the 193 
study APIs between the point of use and the point at which surface water was sampled for the 194 
four study sites. Estimates of use of APIs were based on UK usage in 2009 (IMS Health, 195 
2012) and were expressed as a per capita consumption per day (derived using the estimated 196 
UK population of 61,126,832; Eurostat, 2012). The LF2000-WQX model was run for all of 197 
the monitoring study sites, using only the per capita usage data (Table 1). It was assumed that 198 
all the prescribed drugs were consumed and excreted and that there was no removal in the 199 
STPs. For each API, percentage effective removals were calculated by dividing the measured 200 
value for an API at each of the study sites by the predicted mean value for the specific site.  201 
To allow comparison of the inverse modelling removal estimates with removal estimates 202 
from the ‘standard’ forward approach to API exposure modelling, removal percentages were 203 
also calculated for each of the monitoring study sites based on published data on metabolism, 204 
removal in treatment and dissipation in surface waters (Table 3). Where a range of values 205 
were reported for these input parameters, lowest and highest values were used to produce 206 
‘worst’ and ‘best’ case estimates of removal. For use in broader modelling, a correction was 207 
made, using dissipation data from Table 3, to the inverse modelled removal rates to account 208 
for the in stream-dissipation of a study compound between the points of emission to the 209 
catchments and the monitoring points.  210 
 211 
1.4. Evaluation of modelling approach against monitoring data 212 
To evaluate the performance of the approach, predictions of concentrations in river 213 
catchments in England and Wales were compared with measured environmental 214 
concentrations from a range monitoring studies that have been performed in the UK over the 215 
past eleven years
 
(Boxall et al., 2012b; Hilton et al., 2003; Ashton et al., 2004; Thomas and 216 
Hilton, 2004; Bound and Voulvoulis, 2006; Roberts and Bersuder, 2006; Roberts and 217 
Thomas, 2005; Kasprzyk-Hordern et al., 2007 and 2009; Kasprzyk-Hordern and Baker, 2012; 218 
Zhang and Zhou, 2007; Zhou et al., 2009; Table 4). Mean concentrations were then obtained 219 
for each sampling point and these mean MECs were then collated into one single distribution 220 
using the approach described by Straub
 
(2008) and Metcalfe et al.
 
(2008). Median and upper 221 
and lower quartiles were derived for the concentration distributions. Concentrations of 222 
monitored APIs were then estimated for all river reaches in the monitored catchments using 223 
the mean, minimum and maximum removal rates that were derived from the inverse 224 
modelling and corrected for in stream dissipation. Concentration distributions and associated 225 
summary statistics from the monitoring data analyses and the modelling were then compared. 226 
  227 
1.5. Assessment of pharmaceutical risks to aquatic systems in England and Wales 228 
The average, maximum and minimum removal estimates and corrected for in-stream 229 
dissipation data were then used in the LF2000-WQX model to predict concentrations of the 230 
12 study APIs in 3117 river reaches distributed across 22 large catchments in England and 231 
Wales serving a population of 21 million people. Annual mean predicted environmental 232 
concentrations (PECs) were obtained for each pharmaceutical for every reach in each 233 
catchment.  234 
To assess the implications of the predicted exposure distributions in terms of ecological risks, 235 
data on the acute and chronic (growth and reproduction) toxicity of the study APIs to algae, 236 
invertebrates and fish were extracted from the literature (Table 5). With the exception of 237 
naproxen, these data were used to derive predicted no-effect concentrations (PNECs) for each 238 
study pharmaceutical using assessment factors recommended by the European Chemicals 239 
Agency
 
(ECHA, 2010). Studies reporting non-regulatory endpoints (e.g. biomarker, 240 
histological and behavioural responses) were not considered in the derivation of PNECs. For 241 
naproxen, the Environmental Reference Concentration (ERC) proposed by Murray-Smith et 242 
al
 
(2012) was used. Risk characterisation ratios (RCRs) were then calculated for each river 243 
reach using equation 4. 244 
 245 
ERCPNEC
PEC
 RCR 
or  
           Equation 4 246 
 247 
Estimated RCRs for all the reaches in all the 22 catchments were then combined in order to 248 
develop risk distributions for each pharmaceutical. An RCR ≥1 was considered as indicative 249 
of an unacceptable risk posed by an API to the aquatic population in a reach. In the past, 250 
diclofenac has been identified as a potential priority substance under the European Water 251 
Framework Directive and an environmental quality standard (EQS) of 0.1 g/l was proposed 252 
for this API. Therefore, in addition to deriving RCR distributions for diclofenac, we also 253 
compared exposure predictions to the proposed EQS value to see what the implication of the 254 
EQS would have been had it been introduced. 255 
 256 
2. Results 257 
2.1. Comparison of removal using  forward with removal based on monitoring data at the 258 
study sites 259 
Mean inverse modelling-based estimates of removal between the point of prescription/sale 260 
and the point of monitoring into the surface waters for the monitoring study sites ranged from 261 
90.63 (carbmazepine) to 99.86% (ibuprofen) (Table 6). Concentrations of cyclophosamide, 262 
fluoxetine, ketoprofen, orlistat and simvastatin were below detection limits in the monitoring 263 
study, so it was only possible to estimate a minimum removal rate for these substances – 264 
these were all greater than 95.5% (Table 6). In comparison, estimates of effective removal, 265 
based on forward modelling using data on usage, metabolism and dissipation in wastewater 266 
treatment and surface waters resulted in ‘worst’ case estimates of between 4 (atenolol) and 267 
97.1% (naproxen) and ‘best’ case estimates of between 70.2 (trimethoprim) and 99.8% 268 
(ibuprofen) removal between use by the patient and the sampling points for the four study 269 
sites (Table 6). Mean percentage removal values for carbamazepine, diclofenac, fluoxetine, 270 
furosemide and trimethoprim, obtained from usage, metabolism and wastewater and surface 271 
water dissipation data were lower than removal values obtained using inverse modelling of 272 
the monitoring data and for selected compounds (e.g. trimethoprim), there was a large 273 
difference between the two approaches. Due to a lack of data, it was not possible to estimate 274 
removal percentages for cyclophosphamide, ketroprofen, orlistat and simvastatin using the 275 
forward modelling approach.  276 
Correction of the inverse modelling data for in-stream dissipation of the study compounds 277 
indicated that on average between 90.01 (atenolol) and 99.84% (ibuprofen) is removed 278 
between the point of prescription/use and the points of emission from treatment plants within 279 
the monitoring study catchments (Table 6). With the exception of atenolol where on average 280 
3% of the compound was estimated to have dissipated in the rivers within the catchment, in-281 
stream dissipation was found to actually play a negligible role in the overall dissipation of the 282 
study compounds and the monitoring sites. Never-the-less, the corrected values were 283 
employed in the subsequent landscape scale exposure modelling. 284 
 285 
2.2. Comparison of exposure predictions against monitoring data 286 
It was possible to obtain good datasets on mean concentrations of atenolol, carbamazepine, 287 
diclofenac, ibuprofen and trimethoprim in surface waters at different points within 10 288 
catchments allowing concentration distributions to be derived (Figure 1). Mean, minimum 289 
and maximum estimated removal rates between the point of use and emission to surface 290 
waters were used in the LF2000-WQX model to estimate mean concentrations of the study 291 
compounds for every river reach in the 10 monitored catchments in England and Wales. 292 
Summary statistics for the distributions of mean predicted concentrations for all river reaches 293 
in the monitored catchments, obtained from the modelling, are shown in Table 7. With the 294 
exception of ibuprofen, there was good agreement between the monitored and modelled 295 
distributions (Table 7; Figure 1). For ibuprofen, the modelled median concentrations and 296 
upper and lower quartiles for the distributions were substantially smaller than the summary 297 
statistic values obtained from monitoring studies.  298 
 299 
2.3. Assessment of risks of APIs to surface waters in England and Wales 300 
To assess the implications of the distributions of concentrations of the APIs, concentrations 301 
were used alongside ecotoxicity data to characterise the level of risk posed by each API in 302 
each of the river reaches modelled. Risk characterisation ratios for the study APIs for the 22 303 
catchments (Figure 2) show that, for trimethoprim, furosemide, diclofenac and atenolol, 304 
RCRs were 0.008 or lower, indicating that these substances pose a very low risk to aquatic 305 
systems in England and Wales (Figure 2A). While the maximum RCRs of greater than one 306 
were obtained for carbamazepine, fluoxetine and simvastatin in one of the 3312 river reaches 307 
and for orlistat in 12 river reaches, simvastatin exceeded one, in the vast majority of reaches a 308 
RCRs were lower than one indicating that these substances generally pose an acceptable risk 309 
to the aquatic environment. For orlistat, simvastatin and fluoxetine, exposure estimates are 310 
based on limits of detection so in reality RCRs will be lower still. However, the maximum 311 
RCR for ibuprofen was 174 and, for this compound, 49.5% of river reaches across the 22 312 
catchments were predicted to be at risk. When the catchments were considered individually 313 
(Figure 2B), nine of the catchments were found to have median concentrations for ibuprofen 314 
greater than the PNEC. The proposed EQS for diclofenac is 320-times lower than the 315 
calculated PNEC. Comparison of this value with the exposure data suggested that 4.5% of 316 
river reaches in the 22 catchments would have concentrations higher than the proposed 317 
standard (Figure 2A), while none would have a concentration higher than the PNEC. 318 
 319 
3. Discussion 320 
A number of studies over the past few years have applied modelling approaches to predict the 321 
occurrence and risks of APIs in surface waters in different regions of the world
 
(Williams et 322 
al., 2009; Hannah et al., 2009; Letzel et al., 2009). Typically, the modelling uses information 323 
on the usage of an API in an area, metabolism, fate in wastewater treatment systems and fate 324 
in receiving waters to estimate surface water concentrations. Comparison of estimates of 325 
removal, obtained using these information, with estimates of total removal, obtained using 326 
inverse modelling based on monitoring data for the four study sites, indicates that the 327 
standard modelling approach can either over- or under-estimate removal of pharmaceuticals 328 
in the real environment. This is probably one reason why previous studies have often shown 329 
little correlation between measured and modelled data (e.g. Metcalfe et al. 2008). The 330 
mismatch between the inverse modelled removal rates and rates obtained from usage, 331 
metabolism and dissipation data are likely explained by a number of factors, including: not 332 
all of a prescribed API is released to the wastewater system; metabolism in the actual 333 
population is greater or lower than indicated by literature studies on a few individuals; and 334 
variability in the types and performance of wastewater treatment works. When ranges of 335 
values are available for a particular model input parameter, there were also large differences 336 
between the maximum and minimum removal percentages for some compounds. This was 337 
particularly true for atenolol and furosemide, where removal was estimated to range from 4.0 338 
to 97.9% and from 10 to 77.5%, respectively, highlighting the difficulty in selecting model 339 
input data. Smaller variation was seen for the inverse-modelling derived total removal rates 340 
across the four study sites. Differences in demographic characteristics and the treatment 341 
technologies across the sites may contribute to the differences between the forward and 342 
inverse modelling derived values across the sites.  343 
For six of the seven study compounds, where extensive datasets were available on 344 
concentrations in rivers in England and Wales, there was close agreement between the results 345 
of the exposure modelling and the monitoring data. The disagreement between modelled and 346 
measured distribution statistics for ibuprofen may be partly explained by the fact that the 347 
ibuprofen monitoring dataset was dominated by measurements made in 2003 during periods 348 
of low precipitation when dilution of effluent through the wastewater treatment plants and 349 
dilution by receiving waters would be small. In addition, IMS Health data indicate that usage 350 
of ibuprofen in 2003 was higher than in 2009 when our study was performed (i.e. 293,802 kg 351 
in 2003 compared with 277,465 kg in 2009). There have also been significant advances in 352 
analytical methodologies since 2003, which have reduced the occurrence of analytical 353 
artefacts such as matrix interferences. In a recent large-scale monitoring study involving 354 
analysis of around 8,000 samples of undiluted wastewater effluents at over 160 treatment 355 
works, median concentrations for ibuprofen have been reported to be 330 ng/l (95 percentile 356 
concentration = 2.48 µg l
-1
) suggesting the monitoring data from the earlier study are likely 357 
not typical of concentrations across the broader landscape (UKWIR, 2012). The inverse 358 
model results better reflect the much smaller values measured for ibuprofen in the most 359 
recent monitoring studies performed in 2006, 2007 and 2009. 360 
PNECs were derived from available acute and chronic ecotoxicity studies using standard 361 
endpoints such as mortality, reproduction and growth and assessment factors recommended 362 
by ECHA. Numerous studies have also explored effects of APIs on non-standard endpoints 363 
such as behaviour, histology and biochemical effects, sometimes at concentrations much 364 
lower than the standard endpoints
 
(Hoeger et al., 2005; Ankley et al., 2007; Stanley et al., 365 
2007; Boxall et al., 2012b). However, in this study we did not use these data to inform the 366 
PNEC derivation. This approach is consistent with the recent Technical Guidance Document 367 
for deriving Environmental Quality Standard (EQSs) in the scope of the European Water 368 
Framework Directive
 
(EQS-TGD, 2011). With the exception of diclofenac, these non-369 
standard effects are seen at concentrations higher than the estimated PNECs, providing re-370 
assurance that the PNEC values for most of the study substances are protective against more 371 
subtle effects. For diclofenac, the EQS value is slightly higher than concentrations where 372 
histological and biochemical effects have been reported. A recent study (Memmert et al., 373 
2103) has questioned the reliability of the conclusions on the histopathology studies on which 374 
the EQS is based and it is possible that the EQS is overly conservative. 375 
With the exception of ibuprofen, where a risk was identified for 49.5% of river reaches, 376 
RCRs for the other study compounds in river reaches in England and Wales were generally 377 
lower than one (for carbamazepine, orlisat, fluoxetine and simvastatin a risk was identified in 378 
one, one and 12 of the 3312 river reaches respectively), indicating that the other compounds 379 
pose an acceptable risk to the UK environment. The findings for ibuprofen agree with 380 
conclusions from other studies into the risks of APIs in aquatic systems, where ibuprofen has 381 
been highlighted as a drug of potential concern in river systems
 
(Christensen et al., 2009; 382 
Lienert et al., 2007). We would therefore advocate that further work is carried out to explore 383 
the wider occurrence of ibuprofen in surface waters in England and Wales and to explore 384 
whether effects are occurring in the catchments where a significant proportion of river 385 
reaches are predicted to be at risk; the PNEC may also need to be re-assessed as well. 386 
Comparison of exposure predictions for diclofenac with the previously proposed EQS for 387 
diclofenac, indicated that 4.5% of river reaches would have exceeded the EQS had it been 388 
adopted. This percentage is in agreement with the value of 3-5% previously predicted for 389 
EQS exceedences in rivers in England using the forward modelling approach (Johnson et al., 390 
2013).  391 
Overall, this study demonstrates the potential of using inverse modelling alongside 392 
monitoring data to generate model input data in exposure and risk assessment. As a total 393 
removal rate is estimated for a broad scale, the approach offers a number of advantages, i.e. it 394 
takes into account factors such as the non-use of prescribed drugs by patients; it addresses 395 
differences in metabolism across the population; it accounts for dissipation processes in the 396 
local sewerage network and it accounts for differences in effectiveness of different 397 
wastewater treatment technologies in a catchment. The four study sites used in this study 398 
were based in four different counties located in the South East and Midland regions of 399 
England so the approach appears to be effective at estimating exposure for different regions 400 
in a country the size of England. This is backed up by the comparisons of exposure 401 
predictions for the catchments that have been monitored in England and Wales with the 402 
experimentally-derived data.  403 
The approach is, however, reliant on the availability of good quality monitoring data and 404 
cannot be applied to compounds that are not yet in use. Cultural and demographic differences 405 
might mean that the total removal predictions from this study cannot be applied to other 406 
countries. However, there is no reason why a similar monitoring and modelling strategy to 407 
that employed in the current study could not be applied elsewhere in order to generate state- 408 
or country-specific removal rates and hence assess the broad scale exposure risks of APIs in 409 
other regions of the world. The concept could also be applied at different stages in the 410 
pathway of a pharmaceutical from the patient to environmental receptors to better understand 411 
key dissipation processes for pharmaceuticals to inform future modelling initiatives. 412 
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Table Legends 
Table 1. Usage and mean concentrations (expressed in ng l
-1
) measured at the four study sites. 
Values in parentheses for the study sites indicate the measured concentration range over the 
12 month study period (Measured data taken from Boxall et al, 2012a).  
Table 2. Characteristics of study catchments in terms of population served, types of sewage 
treatment plants present and average residence time between discharge points and the 
monitoring points. 
Table 3. Information on percentage of API excreted, percentage API removed in wastewater 
treatment removal rates, and half lives for in stream dissipation used in the modelling of the 
study APIs.  
Table 4. Summary of the monitoring studies used in the evaluation of the modelling 
approach. 
Table 5. Ecotoxicological data used alongside the model predictions to establish the level of 
risk of the study compounds across the 18 study catchments in England and Wales. 
Table 6. Summary of removal percentages for the 12 study APIs at the monitoring sites, 
obtained using the inverse modelling approach and the traditional forward modelling 
approach. 
Table 7. Comparison of summary statistics for modelled and measured distributions of mean 
concentrations of APIs for river reaches in catchments that have been monitored for APIs in 
England and Wales.  
 
Figure legends 
 
Figure 1. Cumulative distributions of mean concentrations of pharmaceuticals in river reaches 
in catchments in England and Wales derived from the LF2000-WQX model or from 
monitoring data. Modelled distributions are developed for the catchments where a 
pharmaceutical has been monitored and are based on mean,  maximum and minimum 
inverse-modelled rates of removal. Monitoring data were taken from: Hilton et al., 2003; 
Ashton et al., 2004; Thomas and Hilton, 2004; Bound and Voulvoulis, 2006; Roberts and 
Bersuder, 2006; Roberts and Thomas, 2006; Kasprzyk-Hordern et al., 2007, 2009, 2012; 
Zhang and Zhou, 2007; Zhou et al., 2009; Boxall et al., 2012. In instances where a number of 
samples were taken from sites in a catchment, mean concentrations were estimated for each 
site. If a measured concentration was reported as < LOD then half of the LOD was used in 
the calculation of means. 
 
Figure 2. Box and whisker plots (indicating median, upper and lower quartile and maximum 
and minimum values) of PEC/PNEC ratios for A) a range of APIs, obtained from LF-2000-
WQX exposure predictions for 2950 river reaches across 22 large river catchments in 
England and Wales and PNEC values derived from published literature on the effects of the 
study compounds on aquatic organisms. Removal rates for the grey bars were based on non-
detect data so are a ‘worst’ case indication of risks; and B) for ibuprofen in the individual 18 
large river catchments modelled in England and Wales.  
 
Table 1.  
Compound Class Use in UK in 2009 
(Kg/yr) 
Site 1 
 
Site 2 
 
Site 3 
 
Site 4 
 
Atenolol β-blocker 32944 43.8 (18.1 – 66.3) 54.2 (31.2 – 91.2) 26.7  (8.2 – 67.6) 41.1  (19.6 – 114) 
Carbamazepine anti-epileptic 49781 103.6  (49.4 – 199) 138.8(45.0 – 277) 272.3 (34.3 – 555) 182.6 (16.4 – 480) 
Cyclophosphamide chemotherapy agent 281 <1 <1 <1 <1 
Diclofenac non steroidal anti-inflammatory 34720 10.3 (<10 – 24.3) 18.1 (<10 – 39.0) 20.5 (<10 – 76.3) 15.9 (<10 – 47.1) 
Fluoxetine antidepressant 6377 <5 <5 <5 <5 
Furosemide diuretic 20872 10.2 (<5 – 28.9) 19.8 (6.59 – 43.1) 9.1 (<5 – 36.0) 17.4 (5.34 – 63.5) 
Ibuprofen non steroidal anti-inflammatory  277466 17.6 (6.33 – 30.8) 11.8 (<2 – 38.4) 8.4 (<2 – 21.5) 18.2 (<2 – 38.2) 
Ketoprofen non steroidal anti-inflammatory 1878 <1 <1 <1 <1 
Naproxen non steroidal anti-inflammatory 67672 18.2 (10.2 – 26.4) 18.1 (6.93 – 42.2) 13.6 (4.85 – 28.9) 23.1 (11.1 – 44.4) 
Orlistat anti-obesity 16669 <10 <10 <10 <10 
Simvastatin hypolipidemic 50070 <50 <50 <50 <50 
Trimethoprim antibiotic 13094 10.0 (<5 – 13.8) 9.5 (<5 – 13.8) 4.1 (<5 – 8.27) 8.9 (<5 – 26.4) 
 
Table 2.  
Site Location Population Number of 
treatment plants 
upstream of 
sampling point 
Types of 
STPs
†
 
Average water 
residence 
between 
discharge and 
sampling (d) 
1 Midlands 402227 17 SAS 1 
SB 5 
TA 3 
TB 8 
1.27 
2 Southern England 2071445 81 SAS 12 
SB 22 
TA 19 
TB 28 
2.33 
3 Southern England 395581 27 SAS 2 
SB 11 
TA 8 
TB 6 
2.42 
4 South East 
England 
177801 14 SAS 2 
SB 3 
TA 4 
TB 5 
1.46 
†General classification of sewage treatment plants: SAS - Secondary Activated Sludge; SB - 
secondary biological filter; TA - Activated Sludge with tertiary treatment; TB - Biological filter with 
tertiary treatment. 
  
Table 3.  
Compound Proportion of 
administered 
compound excreted 
by patient (%) 
Proportion of compound 
removed in wastewater 
treatment plants 
Dissipation half-life in 
receiving water (d) 
Atenolol 69 – 96  -93 - 97 3 - 30 
Carbamazepine 26 – 31 -122 – 58 82 - 100 
Cyclophosphamide 2.5 – 20 0 43 
Diclofenac 6 – 26 -143 – 80 5 
Fluoxetine 20 – 26 33 112 – 113 
Furosemide 90 -119 – 75 - 
Ibuprofen 11 – 47 52 – 99.7 ~20 
Ketoprofen - 40–100 - 
Naproxen 0.6 – 5.6 48 – 93 10.2 – 14.6 
Orlistat 83.1 ~90 - 
Simvastatin - -17 – 91 7.8 
Trimethoprim 50 – 70 -40 – 40.4 5.7 – 100 
Data collated from: Anderson et al., 2004; Andreozzi et al., 2003; Araujo et al., 2011; Bagley et al., 1973; Boxall et al., 
2002;  Bürge et al., 2003; Buser et al., 1999; Garcia-Ac et al., 2009; ; Gros et al., 2010; Heberer et al., 2002; Kasprzyk 
Hordern, 2012; Kovalova et al., 2011; Kwon; & Armbrust, 2006; Küster et al., 2010; Lam et al., 2004, LeClerq et al., 2009; 
Lee et al., 2009;  Lienert et al., 2007; Paffoni et al., 2006, Paxeus, 2004; Piecha et al., 2010; Roche, unpublished; Runkel et 
al., 1972;  Sipma et al., 2010; Ternes et al., 2001; Upton et al., 1980; Wu et al., 2011; Yamamoto, 2009; Zhi et al., 1995; 
Zuccato et al., 2001. 
  
Table 4.  
Compound River catchments References 
Atenolol Blackwater, Derwent, Ely, Great Ouse, 
Taff, Thames 
1,2 
Carbamazepine Blackwater, Derwent, Ely, Great Ouse, 
Taff, Thames 
1-3 
Diclofenac Blackwater, Derwent, Ely, Great Ouse, 
Lea, Nene, Sussex Ouse, Taff, Thames, 
Welland 
1-4 
Furosemide Blackwater, Derwent, Ely, Great Ouse, 
Taff, Thames 
1,2 
Ibuprofen Blackwater, Derwent, Ely, Great Ouse, 
Lea, Nene, Sussex Ouse, Taff, Thames, 
Tyne, Welland 
1-6 
Naproxen Blackwater, Derwent, Ely, Great Ouse, 
Taff, Thames 
1,2 
Trimethoprim Blackwater, Derwent, Ely, Great Ouse, 
Lea, Nene, Taff, Thames, Tyne, Welland 
1-3,6 
1-Kasprzyk Hordern et al., (2008); 2- Boxall et al., (2012); Zhang and Zhou (2007); 4- 
Environment Agency (2003); 5 – Bound and Volvoulis (2006); 6 – Roberts and Thomas 
(2006) 
Table 5. 
 Test EC50 (mg/l) NOEC (mg/l) AF 
(REACH) 
PNEC (µg/l) Source 
Atenolol Pseudokirchneriella subcapitata 72 h growth 
Daphnia magna 21 d reproduction 
Daphnia magna 21 d second generation 
reproduction test started with 1
st
 gen. brood 
Pimephales promelas 32 d hatching, 
survival, growth 
 128.8 
8.872 
1.48 
 
3.2 
 
 
10 
 
 
 
148 
 
Küster et al., 2010 
Küster et al., 2010 
Küster et al., 2010 
 
Winter et al., 2008 
Carbamazepine Daphnia magna 48 h 
Pseudokirchneriella subcapitata 96 h growth 
Ceriodaphnia dubia 7 d reproduction 
Danio rerio 10 d ELS 
13.8  
100 
0.025 
25 
 
 
10 
 
 
2.5 
Ferrari et al., 2009 
Ferrari et al., 2003 
Cyclophosphamide Pseudokirchneriella subcapitata 96 h growth 
Daphnia magna 48 h immobilisation 
Daphnia magna reproduction  
930 
>1000 
 
 
56 
100 560 Zounkova et al., 2007; SFT, 2006 
Diclofenac Proposed EQS under the Water Framework 
Directive 
   0.1 SCHER, 2011a 
 Rainbow trout reproduction  0.32 10 32 Novartis (personal comm) 
 Zebra fish reproduction  0.32 10 32  
Fluoxetine Daphnia magna chronic 
Danio rerio reproduction  
Desmodesmus subspicatus growth 
Thamnocephalus platyurus 24 h  
 0.089 
0.0032 
0.0006 
0.76 
 
 
10 
 
 
0.06 
Brooks et al., 2005; Lister et al., 2009; 
Oaks et al., 2010 
 
Nalecz-Jawecki, 2007 
Furosemide Pseudokirchneriella subcapitata 96 h growth 
Daphnia magna 48 h immobilisation 
 
60.62 
70 1000 70 Isidori et al., 2006 
Ibuprofen Scenedesmus subspicatus 72 h growth 
Daphnia magna 21 d reproduction 
Oryzias latipes 120 d (post hatch) survival  
342  
<1.23 
0.0001 
10 0.01 Han et al., 2010; Cleuvers, 2004 
Naproxen Daphnia magna 48 h 
Lepomis macrochirus 96h 
Pseudokirchneriella subcapitata 96 h growth 
Ceriodaphnia dubia 7 d reproduction 
ERC value developed from chronic studies 
37 
560 
 
 
0.032 
0.032 
 
 
 
100 
 
 
 
 
4.2 
Straub and Stewart, 2007 
 
Brun et al., 2006 
 
Murray-Smith et al, 2012 
  
 Test EC50 (mg/l) NOEC (mg/l) AF 
(REACH) 
PNEC (µg/l) Source 
Orlistat Selenastrum capricornutum 10 d 
Daphnia magna 21 d NOEC 
Oncorhyncus mykiss 96 h  
 
 
>18.5 
1.92 
0.0016 
 
50 
 
0.032 
GSK 2008 
Simvastatin Dunaliella tertiolecta 96 h EC50 
Fundulus heteroclitus 96 h EC50 
Palaemonetes pugio 
22.8 
2.68 
1.18 
  
 
1000 
 
 
1.20 
Delorenzo and Fleming, 2008 
Key et al., 2009 
Trimethoprim Pseudokirchneriella subcapitata 72 h 
8 species of cyanobacteria 144 h 
Daphnia magna 21 d reproduction 
Oryzias latipes 96 h 
 
 
 
>100 
16 
3.1–200 
6 
20 
 
50 
 
62 
Yang et al., 2008 
Ando et al., 2007 
Park & Choi, 2008 
Kim et al., 2007 
 
Table 6. 
Compound Removal between point of use and 
point of monitoring using inverse 
modelling (%) 
‘Best’ and ‘Worst’ case removal 
between point of use and monitoring 
points based on published metabolism, 
treatment and dissipation data (%) 
Inverse modelled removal rate 
corrected for in-stream dissipation (%) 
Atenolol 93.92 (86.94-97.27)  4.0 – 97.9 90.92 (81.87-95.28) 
Carbamazepine 90.63 (85.20-96.07)  69.0 – 89.1 90.01 (84.89-93.95) 
Cyclophosphamide 95.36 (93.75-96.73) — 94.74 (93.75-95.38) 
Diclofenac 98.24 (97.20-99.42)  74.0 – 95.2 97.64 (96.51-99.00) 
Fluoxetine 98.97 (98.63-99.26)  82.6 – 86.6 98.87 (98.66-99.03) 
Furosemide 98.18 (96.67-99.10)  10 – 77.5 97.67 (95.81-98.82) 
Ibuprofen 99.86 (99.81-99.92)  77.4 – 99.97 99.84 (99.80-99.91) 
Ketoprofen 99.31 (99.07-99.50) — 99.25 (99.11-99.37) 
Naproxen 99.18 (98.74-99.48)  97.1 - 99.6 99.01 (98.59-99.31) 
Orlistat 98.11 (97.45-98.63) — 97.94 (97.52-98.30) 
Simvastatin 98.42 (97.86-99.02) — 98.01 (97.52-98.38) 
Trimethoprim 97.85 (96.39-99.07) 30-70.2 97.14 (95.54-98.73) 
 
Table 7. 
 Median concentration (ng/l) Lower quartile 
concentration (ng/l) 
Upper quartile 
concentration (ng/l) 
 Monitoring 
data 
Modelled 
data 
Monitoring 
data 
Modelled 
data 
Monitoring 
data 
Modelled 
data 
Atenolol 140 92 46 43 435 172 
Carbamazepine 61 193 14.5 89 265 321 
Diclofenac 20 24 6.4 11 61 46 
Furosemide 10.4 19 3.1 8.9 34 32 
Ibuprofen 125 14 25 6.4 475 26 
Naproxen 13 24 4.2 11 42 46 
Trimethoprim 6.7 11 2.1 4.9 21 21 
 
 
    = mean measured concentration 
    = mean predicted distribution of concentrations 
…..   = maximum and minimum predicted distribution of concentrations 
Fig. 1
Fig. 2
